SeeThruEquity Initiates Research Coverage on DelMar Pharmaceuticals, Inc.

Jan 13, 2014, 09:00 ET from SeeThruEquity

NEW YORK, Jan. 13, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

"DelMar's lead drug candidate, VAL-083, is a novel alkylating agent representing a "first in class" small-molecule chemotherapeutic. DelMar initiated clinical trials on VAL-083 in October 2011 as a potential new treatment for glioblastoma multiforme ("GBM"), the most common and aggressive form of brain cancer" stated Ajay Tandon, CEO of SeeThruEquity. "DelMar is currently conducting a Phase I/II trial for VAL-083 and recently released a trial update at the annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Our analysis indicates a price target of $4.53 per share, which is detailed in our report."

The report is available to SeeThruEquity Select Members on SeeThruEquity's website at http://www.seethruequity.com and can be directly accessed here: DMPI Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack's. The report will also available on these platforms.

The investment opinions expressed in its report are solely those of SeeThruEquity. SeeThruEquity has not been compensated for the preparation of its initiation report by any third party or by DMPI.  SeeThruEquity has been compensated for the preparation and dissemination of this press release.

About SeeThruEquity

SeeThruEquity is an investment research and corporate access firm focused on smallcap and microcap public companies. The research is unbiased and not paid for research. The company does not do any investment banking or trading and does not own any of the stocks it covers. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack's. The firm also distributes its research to an audience of opt-in investors and has over 50 companies under coverage. SeeThruEquity also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information visit www.seethruequity.com.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. For more information, please visit http://www.delmarpharma.com.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

SOURCE SeeThruEquity



RELATED LINKS

http://www.seethruequity.com